VEGFA and non-small cell lung carcinoma: In a mouse model of metastatic renal carcinoma, neutralization of VEGF by bevacizumab reduced the CD11b+VEGFR1+ population of MDSCs in the peripheral blood.665 Clinical studies further confirmed that bevacizumab could decrease the number of G-MDSCs, whereas increase the numbers of mature circulating DCs in patients with metastatic CRC, as well as in patients with NSCLC and patients with RCC.666,667